HTG Molecular Diagnostics has entered a new Master Collaboration Agreement for translational programs with Merck KGaA.    The agreement complements the previously announced Master Companion Diagnostic Agreement with Merck KGaA and includes a statement of work with EMD Serono, the biopharmaceutical business of Merck KGaA in the United States and Canada.   “We are pleased to expand our relationship with Merck KGaA, Darmstadt, Germany, into earlier research stages of their programs,...